A picture containing text, clipart

Description automatically generated

**Entos Pharmaceuticals, Inc.**

A new reality in genetic medicine lies ahead, one that will be ushered in with the advent of safe, effective, and redosable nucleic acid delivery technologies. With our partners, such as Eli Lilly, we are developing next-generation genetic medicines using our proprietary Fusogenix proteolipid vehicle (PLV) drug delivery system. Fusogenix PLVs are formulated with FAST proteins to enable the delivery of mRNA or DNA into target cells through direct fusion. For more information, visit [www.entospharma.com](https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.entospharma.com%2F&esheet=52588923&newsitemid=20220303005276&lan=en-US&anchor=www.entospharma.com&index=4&md5=b6d335cae798d9329e08288f7f036ced).

**Contact info**

**Corporate Contact:**

John Lewis, Ph.D.

CEO, Entos Pharmaceuticals

[info@entospharma.com](mailto:info@entospharma.com)

**Media Contact:**

Perrin Beatty, Ph.D.

Communications Lead

[media@entospharma.com](mailto:media@entospharma.com)

**Canadian Headquarters**

Unit 4550, 10230 Jasper Avenue

Edmonton, Alberta, Canada

T5J 4P6

**USA Headquarters**

3040 Science Park Road, Suite 1100

San Diego, CA 92121

**UK Headquarters**

33 St James's Square

London, UK

SW1Y 4JS

**General Contact**

1-800-727-0884

info@entospharma.com

**Conference objective**

Network with investors, industry, Canadian government officials, and media to 1) promote Entos and its Fusogenix PLV drug delivery technology, 2) increase funding for the development and biomanufacturing of Canadian-made genetic medicines and vaccines, and 3) highlight Entos as an emerging industry leader in the resurgence of genetic medicines